NIR-Responsive Mitochondrial-Targeted Nanozymes With Built-In Antibacterial Function for Safe Osteoarthritis Therapy.

Cui J, Han H, Man Z, Gao Y, Liu J, Li R, Zhang Y, Lu S, An Z, Chen L, Pang K, Zhao Z and 4 more

Show all authors

Lei P, Wang G, Zhang P, Li W

Advanced healthcare materials24 Sept 2026

PMID42786626DOI10.1002/adhm.71754PepBankPUB-42786626

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
CuQ@SS31 effectively alleviated oxidative stress in osteoarthritis models.
In plain wordsIn osteoarthritis models, a copper-quercetin nanozyme carrying SS31 lowered oxidative stress.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative stress
Study
n: not reported in source
Outcome group
Inflammation markers · Musculoskeletal
Source sentences
Summary
CuQ@SS31 effectively alleviated oxidative stress, suppressed inflammation, and decelerated cartilage degradation, while demonstrating prolonged joint retention and a favorable safety profile.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662605
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
CuQ@SS31 suppressed inflammation in osteoarthritis models.
In plain wordsIn osteoarthritis models, a copper-quercetin nanozyme carrying SS31 reduced inflammation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammation
Study
n: not reported in source
Outcome group
Inflammation markers · Musculoskeletal
Source sentences
Summary
suppressed inflammation, and decelerated cartilage degradation, while demonstrating prolonged joint retention and a favorable safety profile.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662606
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
CuQ@SS31 decelerated cartilage degradation in osteoarthritis models.
In plain wordsIn osteoarthritis models, a copper-quercetin nanozyme carrying SS31 slowed cartilage breakdown.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseCartilage degradation
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
decelerated cartilage degradation, while demonstrating prolonged joint retention and a favorable safety profile.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662607
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics
CuQ@SS31 showed prolonged joint retention.
In plain wordsIn osteoarthritis models, a copper-quercetin nanozyme carrying SS31 stayed in the joint for a long time.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseJoint retention
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
prolonged joint retention and a favorable safety profile.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662608
05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Safety outcome
CuQ@SS31 showed a favorable safety profile; no event data are given.
In plain wordsIn osteoarthritis models, a copper-quercetin nanozyme carrying SS31 was reported to have a favorable safety profile; no numbers are given.
Peptide
Elamipretide (SS-31)
Outcome
Not applicableSafety profile
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
a favorable safety profile.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662609
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
CuQ@SS31 had almost no effect on heat shock protein 70, unlike free quercetin.
In plain wordsIn cells, a copper-quercetin nanozyme carrying SS31 left the protective heat shock protein 70 almost unchanged.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeHeat shock protein 70
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
Furthermore, CuQ@SS31 has almost no effect on the cell-protective heat shock protein 70 typically associated with free quercetin, thereby preserving essential thermal stress defenses.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662603
07LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Activity measurement
CuQ@SS31 showed inherent antibacterial properties.
In plain wordsIn lab tests, a copper-quercetin nanozyme carrying SS31 showed built-in antibacterial properties.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseAntibacterial activity
Study
n: not reported in source
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
In addition, CuQ@SS31 also exhibits inherent antibacterial properties, reducing potential infection risks from intra‑articular administration.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662604
08LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Activity measurement
The nanozyme CuQ@SS31 (copper, quercetin, SS31) scavenged superoxide anions and hydrogen peroxide through SOD-like and CAT-like catalysis.
In plain wordsIn lab tests, a copper-quercetin nanozyme carrying SS31 cleared superoxide and hydrogen peroxide.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseSOD-like and CAT-like enzymatic activity
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
CuQ@SS31 confers potent dual-enzyme mimetic activities, scavenging superoxide anions and hydrogen peroxide through synergistic SOD-like and CAT-like catalysis.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662601
09LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Activity measurement
The thermal effect of near-infrared irradiation further enhanced the enzymatic activity of CuQ@SS31.
In plain wordsIn lab tests, infrared heating further raised the enzyme-like activity of a copper-quercetin nanozyme carrying SS31.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseEnzymatic activity with near-infrared irradiation
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
Notably, the thermal effect produced by near-infrared irradiation further enhances the enzymatic activity of CuQ@SS31 itself.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4278662602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.